Internal Medicine, Rheumatology · Asheville, NC
NPI
1598984155
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
4 Vanderbilt Park Dr, Suite 200
Asheville, NC, 28803
Phone (828) 258-9533
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.5M
150,192 services
Medicare patients, 2024
457
Average age 74
Drug cost, 2024
$3.2M
3,426 prescriptions
Company payments, 2025
$1,181
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Christopher G Meyer was code J3262 (injection, tocilizumab, 1 mg), 53,480 times for 23 patients. In total Christopher G Meyer billed 150,192 services in 92 codes, and Medicare paid $1.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-05-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 53,480 | 23 | $4.70 | $251K |
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 39,200 | 19 | $3.60 | $141K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 24,700 | 47 | $9.00 | $222K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 13,225 | 39 | $33.78 | $447K |
| J0897 Injection, denosumab, 1 mg | Office | 3,720 | 48 | $20.55 | $76K |
| 82565 Clinical Chemistry | Office | 715 | 311 | $4.97 | $3,550 |
| 85652 Clinical Chemistry | Office | 692 | 288 | $2.64 | $1,824 |
| 85025 Blood Count | Office | 674 | 274 | $7.56 | $5,094 |
| 80076 Clinical Chemistry | Office | 620 | 244 | $7.96 | $4,936 |
| 36415 Venipuncture Blood Collection | Office | 596 | 276 | $8.64 | $5,147 |
| 86140 Clinical Chemistry | Office | 558 | 235 | $5.06 | $2,825 |
| 99214 Office E&M - Established | Office | 552 | 262 | $85.70 | $47K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 484 | 11 | $0.09 | $43.72 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 437 | 235 | $11.86 | $5,181 |
| 96413 Chemotherapy Administration | Office | 325 | 81 | $97.38 | $32K |
By year: 2022 $1.8M for 129,618 services; 2023 $1.7M for 148,136 services; 2024 $1.5M for 150,192 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82565 Clinical Chemistry | 715 | 311 | $4.97 | $3,550 |
| 85652 Clinical Chemistry | 692 | 288 | $2.64 | $1,824 |
| 85025 Blood Count | 674 | 274 | $7.56 | $5,094 |
| 80076 Clinical Chemistry | 620 | 244 | $7.96 | $4,936 |
| 36415 Venipuncture Blood Collection | 596 | 276 | $8.64 | $5,147 |
| 86140 Clinical Chemistry | 558 | 235 | $5.06 | $2,825 |
| 82310 Clinical Chemistry | 108 | 71 | $5.06 | $546 |
| 82306 Clinical Chemistry | 102 | 89 | $29.01 | $2,959 |
| 86235 Immunoassay | 90 | 14 | $16.54 | $1,489 |
| 86481 Immunoassay | 86 | 85 | $96.86 | $8,330 |
Medicare prescription drug claims, 2024
In 2024, the drug Christopher G Meyer prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 630 prescriptions and refills. In total Christopher G Meyer wrote 3,426 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 630 | 1,438 | 159 | $20K |
| Methotrexate Methotrexate Sodium | 571 | 1,210 | 140 | $14K |
| Prednisone Generic | 514 | 792 | 132 | $2,884 |
| Alendronate Sodium Generic | 148 | 391 | 57 | $1,257 |
| Leflunomide Generic | 120 | 260 | 31 | $5,415 |
| Tramadol Hcl Generic | 105 | 114 | 15 | $799 |
| Gabapentin Generic | 99 | 173 | 22 | $1,232 |
| Allopurinol Generic | 71 | 151 | 16 | $553 |
| Sulfasalazine Generic | 68 | 140 | 13 | $1,878 |
| Diclofenac Sodium Generic | 67 | 112 | 17 | $828 |
| Forteo Teriparatide | 59 | 60 | Under 11 | $249K |
| Meloxicam Generic | 52 | 108 | 21 | $219 |
| Simponi Golimumab | 51 | 59 | Under 11 | $350K |
| Enbrel Sureclick Etanercept | 46 | 56 | Under 11 | $429K |
| Otezla Apremilast | 40 | 40 | Under 11 | $194K |
Brand drugs: 597 claims; generic drugs: 2,792 claims; opioid claims: 116.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Christopher G Meyer $1,181 ($1,181 in general payments such as food, travel and fees) from 10 companies. The largest payer was Amgen Inc. with $664.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 33 | $664 |
| E.R. Squibb & Sons, L.L.C. BMY | 15 | $140 |
| Abbvie Inc. ABBV | 6 | $113 |
| Pfizer Inc. PFE | 5 | $78.3 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $52.03 |
| Radius Health, Inc. | 2 | $39.55 |
| Sobi, Inc SOBI.ST | 1 | $27.55 |
| Fresenius Kabi USA, LLC | 1 | $25.99 |
| Janssen Biotech, Inc. JNJ | 1 | $22.98 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $17.85 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.